

DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/DD423ADFB18EN.html>

Date: December 2019

Pages: 35

Price: US\$ 3,500.00 (Single User License)

ID: DD423ADFB18EN

Abstracts

DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2019

SUMMARY

DNA Gyrase Subunit B (EC 5.99.1.3) pipeline Target constitutes close to 6 molecules. The latest report DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2019, outlays comprehensive information on the DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

DNA Gyrase Subunit B (EC 5.99.1.3) - DNA gyrase is an essential bacterial enzyme that catalyzes the ATP-dependent negative super-coiling of double-stranded closed-circular DNA. DNA gyrase has two subunits. One of the subunit is B which introduces negative supercoils. Subunit B is selectively inactivated by antibiotics such as coumermycin A1 and novobiocin. Inhibition of either subunit blocks super twisting activity. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 3 and 1 respectively. Report covers products from therapy areas Infectious Disease which include indications Acinetobacter Infections, Clostridium difficile Infections (Clostridium difficile Associated Disease), Escherichia coli Infections, Bacterial Infections, Klebsiella pneumoniae Infections, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Mycobacterium Infections, Pseudomonas aeruginosa Infections and Tuberculosis.

Furthermore, this report also reviews key players involved in DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary

databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for DNA Gyrase Subunit B (EC 5.99.1.3)

The report reviews DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics and enlists all their major and minor projects

The report assesses DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create

effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for DNA Gyrase Subunit B (EC 5.99.1.3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding DNA Gyrase Subunit B (EC 5.99.1.3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

DNA Gyrase Subunit B (EC 5.99.1.3) - Overview

DNA Gyrase Subunit B (EC 5.99.1.3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

DNA Gyrase Subunit B (EC 5.99.1.3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

DNA Gyrase Subunit B (EC 5.99.1.3) - Companies Involved in Therapeutics Development

Abgentis Ltd

AstraZeneca Plc

Daiichi Sankyo Co Ltd

Spero Therapeutics Inc

DNA Gyrase Subunit B (EC 5.99.1.3) - Drug Profiles

DS-11960558 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-2969 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GYR-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DNA Gyrase B and DNA Topoisomerase IV for Gram Negative Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPR-720 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VXC-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNA Gyrase Subunit B (EC 5.99.1.3) - Dormant Products

DNA Gyrase Subunit B (EC 5.99.1.3) - Product Development Milestones

Featured News & Press Releases

Dec 04, 2019: Spero reports preliminary findings from phase 1 clinical trial of SPR720 and announces plans to advance program into proof-of-concept clinical trial in patients with NTM Pulmonary Disease

Nov 26, 2019: Spero Therapeutics provides new update on SPR720

Jun 17, 2019: Spero Therapeutics to present data for all pipeline programs including SPR-720 at the ASM Microbe 2019 Conference

Feb 26, 2019: Spero Therapeutics receives QIDP Designation from the U.S. FDA for the Development of SPR720

Jan 30, 2019: Spero starts Phase I trial of SPR720 for NTM infections

Nov 05, 2018: Spero Therapeutics announces positive results from SPR720 IND-Enabling studies and plans to initiate a phase 1 Trial

Jun 05, 2018: Spero Therapeutics to Present Data On SPR720 at ASM Microbe 2018

May 30, 2017: Spero Therapeutics Presents New Data on SPR720 at ASM Microbe 2017

May 04, 2017: Spero Therapeutics Receives Grant from National Institutes of Health to Explore Novel Treatment Combinations for Tuberculosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Abgentis Ltd, H2 2019

Pipeline by AstraZeneca Plc, H2 2019

Pipeline by Daiichi Sankyo Co Ltd, H2 2019

Pipeline by Spero Therapeutics Inc, H2 2019

Dormant Projects, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

COMPANIES MENTIONED

Abgentis Ltd

AstraZeneca Plc

Daiichi Sankyo Co Ltd

Spero Therapeutics Inc

I would like to order

Product name: DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/DD423ADFB18EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DD423ADFB18EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970